January 2017

Home  /  2017  /  January

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". The final version of the assessment was published in January 2018.

We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available. The purpose of the assessment is to examine the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in

We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available. Surgical site infection (SSI) is a

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in